Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed (ND) and relapsed/refractory (RR) B-NHL patients. In the presence of T-cells from a healthy donor, epcoritamab demonstrated potent activity against primary tumor cells, irrespective of prior treatments, including CD20 mAbs. Median lysis of 65, 74, and 84% were achieved in diffuse large B-cell lymphoma (n = 16), follicular lymphoma (n = 15), and mantle cell lymphoma (n = 8), respectively. Furthermore, in this allogeneic setting, we discovered that the capacity of B-cell tumors to activate T-cells was heterogeneous and showed an inverse association with their surface expression levels of the immune checkpoint molecule Herpesvirus Entry Mediator (HVEM). In the autologous setting, when lymph node (LN)-residing T-cells were the only source of effector cells, the epcoritamab-dependent cytotoxicity strongly correlated with local effector cell-to-target cell ratios. Further analyses revealed that LN-residing-derived or peripheral blood-derived T-cells of B-NHL patients, as well as heathy donor T-cells equally mediated epcoritamab-dependent cytotoxicity. These results show the promise of epcoritamab for treatment of newly-diagnosed or relapsed/refractory B-NHL patients, including those who became refractory to previous CD20-directed therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Robust preclinical T‐cell–mediated cytotoxicity against tumor cell‐line models and cells from patients with B‐cell non‐Hodgkin's lymphoma (B‐NHL), including diffuse large B‐cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma, has been demonstrated. 2 , 3”
From Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“In an ex vivo study, peripheral or tumor‐resident T cells from patients with B‐NHL showed excellent capacity to induce T‐cell–mediated cytotoxicity in the presence of epcoritamab. 3”
From Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas (2022) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Till, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., Lindgren, C. G., Lin, Y., Pagel, J. M., Budde, L. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387969 · Cited by 529
Bispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2015) · Immunology & Cell Biology · doi:10.1038/icb.2014.93 · Cited by 466
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
Nadler, L. M., Ritz, J., Hardy, R., Pesando, J. M., Schlossman, S. F., & Stashenko, P. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110005 · Cited by 399
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Labrijn, A. F., Meesters, J. I., de Goeij, B. E. C. G., van den Bremer, E. T. J., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S., Kundu, A., Gramer, M. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220145110 · Cited by 339
Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
Sun, L. L., Ellerman, D., Mathieu, M., Hristopoulos, M., Chen, X., Li, Y., Yan, X., Clark, R., Reyes, A., Stefanich, E., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4802 · Cited by 275
Hiraga, J., Tomita, A., Sugimoto, T., Shimada, K., Ito, M., Nakamura, S., Kiyoi, H., Kinoshita, T., & Naoe, T. (2009) · Blood · doi:10.1182/blood-2008-08-175208 · Cited by 257
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Bacac, M., Colombetti, S., Herter, S., Sam, J., Perro, M., Chen, S., Bianchi, R., Richard, M., Schoenle, A., Nicolini, V., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0455 · Cited by 249
Engelberts, P. J., Hiemstra, I. H., de Jong, B., Schuurhuis, D. H., Meesters, J., Beltran Hernandez, I., Oostindie, S. C., Neijssen, J., van den Brink, E. N., Horbach, G. J., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.102625 · Cited by 172
Self-citationSmith, E. J., Olson, K., Haber, L. J., Varghese, B., Duramad, P., Tustian, A. D., Oyejide, A., Kirshner, J. R., Canova, L., Menon, J., et al. (2015) · Scientific Reports · doi:10.1038/srep17943 · Cited by 167
Controlled Fab-arm exchange for the generation of stable bispecific IgG1
Labrijn, A. F., Meesters, J. I., Priem, P., de Jong, R. N., van den Bremer, E. T. J., van Kampen, M. D., Gerritsen, A. F., Schuurman, J., & Parren, P. W. H. I. (2014) · Nature Protocols · doi:10.1038/nprot.2014.169 · Cited by 150
Cited by
Thieblemont, C., Phillips, T., Ghesquieres, H., Cheah, C. Y., Clausen, M. R., Cunningham, D., Do, Y. R., Feldman, T., Gasiorowski, R., Jurczak, W., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01725 · Cited by 584
Hutchings, M., Mous, R., Clausen, M. R., Johnson, P., Linton, K. M., Chamuleau, M. E. D., Lewis, D. J., Sureda Balari, A., Cunningham, D., Oliveri, R. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00889-8 · Cited by 337
Self-citationBispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities
Falchi, L., Vardhana, S. A., & Salles, G. A. (2023) · Blood · doi:10.1182/blood.2021011994 · Cited by 208
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Goebeler, M.-E., Stuhler, G., & Bargou, R. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00905-y · Cited by 177
Linton, K. M., Vitolo, U., Jurczak, W., Lugtenburg, P. J., Gyan, E., Sureda, A., Christensen, J. H., Hess, B., Tilly, H., Cordoba, R., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00166-2 · Cited by 171
Self-citation
Metadata
- Authors
- van der Horst, H. J., de Jonge, A. V., Hiemstra, I. H., Gelderloos, A. T., Berry, D. R. A. I., Hijmering, N. J., van Essen, H. F., de Jong, D., Chamuleau, M. E. D., Zweegman, S., Breij, E. C. W., Roemer, M. G. M., & Mutis, T.
- Affiliations
- Genmab (Netherlands) (NL)
- Amsterdam University Medical Centers (NL)
- Corresponding author
- Mutis, Tuna
- ORCID
- Venue
- Blood Cancer Journal
- Published
- 2021-02-18
- Volume
- 11
- Issue
- 2
- Pages
- 38-38
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC7892878
- OpenAlex
- W3131466578
- Semantic Scholar
- 57447d2bd5996c80db1d89b05d26b364dcdf965e
- Cited by
- 86
- References
- 20
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 29 · 2023: 16 · 2022: 8 · 2021: 10
- FWCI
- 10.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- epcoritamab, B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, anti-CD20 monoclonal antibody, relapsed/refractory lymphoma, T cell cytotoxicity, HVEM, T cell activation, allogeneic T cells, autologous T cells
- MeSH terms
- Antineoplastic Agents, Immunological, B-Lymphocytes, Humans, Lymphocyte Activation, Lymphoma, Follicular, Tumor Cells, Cultured, Lymphoma, Large B-Cell, Diffuse, Antibodies, Bispecific, Antigens, CD20, Lymphoma, Mantle-Cell, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. https://app.cochat.ai/papers/10.1038/s41408-021-00430-6
- The paper
- van der Horst, H. J., de Jonge, A. V., Hiemstra, I. H., Gelderloos, A. T., Berry, D. R. A. I., Hijmering, N. J., van Essen, H. F., de Jong, D., Chamuleau, M. E. D., Zweegman, S., Breij, E. C. W., Roemer, M. G. M., & Mutis, T. (2021). Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer Journal. https://doi.org/10.1038/s41408-021-00430-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.